Promoter holding
64.27%
SP
Synokem Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Synokempharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Synokempharma — 360° Intelligence Report
Generated from MCA filings & public records77/100
Trust Score
Low Risk
Synokempharma is assessed as Low Risk with a Trust Score of 77/100. Synokempharma is an active public limited indian non-government company incorporated in 1983, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Synokem Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
62/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A2).
Charges position: 6 open (200.00 cr) · 3 satisfied (14.75 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 6 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
| Bank Of Maharashtra | 1 | 48.0 cr |
Compliance Score: 62/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- 2 auditor resignation(s) filed - latest: AJAY KAPOOR AND CO on 2023-03-06.
- Delayed payments to MSME suppliers disclosed (803 disclosure(s)).
- 3 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| Gajanan Mohan Shenoy | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VISHAL GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ABHINAV ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| THOMAS BABY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHUBHANGI AGARWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DHIRAJ PODDAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINAY KUMAR PURWAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY KHURANA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Yugal Kishor Chothuram Sikri | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
3
Capital events
1 allotment(s) · 9 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Kemsyn Lifesciences Private Limited | Subsidiary Company | 74.00% |
| Synokem Lifesciences Private Limited | Subsidiary Company | 74.00% |
| Nitin Lifesciences Limited | Subsidiary Company | 74.00% |
Key managerial personnel: ABHINAV ARORA (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 65
Growth signals & trust indicators
Operating for 42+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
6 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 5.46 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence67/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment78/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 6 open charge(s) of 200.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events10 Mar 2026
Charge created
Others - 15.00 cr
31 Jan 2026
Director appointed
Yugal Kishor Chothuram Sikri (Nominee Director)
25 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
31 Jul 2024
Charge created
Axis Bank Limited - 22.50 cr
24 Jul 2024
Director appointed
DHIRAJ PODDAR (Nominee Director)
06 May 2024
Charge created
Others - 15.00 cr
07 Apr 2024
Director ceased
Gajanan Mohan Shenoy
30 Mar 2024
Director appointed
Gajanan Mohan Shenoy (Director)
16 Jan 2024
Charge created
Others - 20.00 cr
22 Sep 2023
Charge created
Others - 115.00 cr
31 Mar 2023
Share transfer (FY 2023)
8.00000000 shares to ABHINAV ARORA HUF
Share transfer (FY 2023)
2372412.00000000 shares to TA INDIA TWO LIMITED
Share transfer (FY 2023)
211431.00000000 shares to TA INDIA TWO LIMITED
Share transfer (FY 2023)
96475.00000000 shares to SURESH RUKMANAND PAREEK
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
9 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A2 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Amol Pharma | U24230RJ1996PTC097657 | Jaipur, Rajasthan, India |
| Swiss Garniers Biotech Private Limited | U24304HP2018PTC007608 | Mehatpur, Himachal Pradesh, India |
| Vasu Healthcare | U24231GJ1980PTC003679 | Baroda, Gujarat, India |
| Sil | L24219HR1993PLC032195 | Haryana, Haryana, India |
| Venusremedies | L24232CH1989PLC009705 | Chandigarh, Chandigarh, India |
| Gufic Biosciences | L24100MH1984PLC033519 | Mumbai, Maharashtra, India |
| Sulphurmills | U24110MH1960PLC011752 | Mumbai, Maharashtra, India |
| Romsons | U24236UP1977PTC004511 | Uttar Pradesh, Uttar Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Synokempharma before audits and certifications: compliance score 62/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Synokempharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Synokempharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Synokempharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Synokempharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Synokempharma an active company?
Synokempharma has MCA status “Active” with a compliance score of 62/100 (Moderate).
Is Synokempharma financially healthy?
Synokempharma has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Synokempharma?
Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Synokempharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 9 active director(s) are on record.
Does Synokempharma have loans or charges against its assets?
6 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.
Is Synokempharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 62/100 (Moderate).
Is it risky to lend to Synokempharma?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
